Poster Session 2-16 Indolent Lymphoma: Treatment (2)

[PS2-16-7] Higher dose of 90Y-ibritumomab tiuxetan demonstrated better efficacy for indolent B cell lymphoma

Eiju Negoro^1,2, Toshiaki Igarashi³, Miyuki Okura², Naoko Ida², Shin Lee^1,2, Kana Oiwa², Kei Fujita², Yasufumi Matsuda², Katsunori Tai², Shinji Kishi⁴, Yoshimasa Urasaki⁵, Naoko Hosono², Takanori Ueda², Takahiro Yamauchi² (1.Cancer Care Promotion Center, University of Fukui Hospital, 2.Department of Hematology and Oncology, University of Fukui, 3.Department of Pharmacy, University of Fukui Hospital, 4.Department of Health and Nutrition, Jin-ai University, 5.Health Administration Center, University of Fukui)